Ligand Pharmaceuticals (LGND) Earnings Analysis

Ligand Pharmaceuticals (LGND) next reports earnings on 2026-08-06, consensus EPS 1.84 USD. Last quarter (2026-05-14) it missed with EPS 1.63 USD vs 1.84 USD est (-11.4%). It has beaten estimates in 4/7 recent quarters (57%). Trailing P/E 38.81.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does LGND next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate1.84 USD
Revenue estimate0.06B

LGND earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-141.63 USD1.84 USD-11.4%Miss
2026-02-262.02 USD1.46 USD+38.4%Beat
2025-11-063.09 USD1.97 USD+56.9%Beat
2025-08-071.6 USD1.54 USD+3.9%Beat
2025-05-081.33 USD1.3 USD+2.3%Beat
2025-02-27-1.64 USD1.37 USD-219.7%Miss
2024-11-07-0.39 USD0.75 USD-152%Miss

Beat rate: 4/7 (57%) over reported quarters with consensus data.

LGND valuation and analyst view

Trailing P/E38.81
Trailing EPS7.723 USD
Price / book6.07
Dividend yield0.00%
Market cap6.13B
Analyst consensusBuy (13 buy / 4 hold / 1 sell)
Avg price target302.17 USD

Related research pages

Frequently asked questions

When is Ligand Pharmaceuticals (LGND)'s next earnings date?

Ligand Pharmaceuticals is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 1.84 USD and revenue estimate of 0.06B.

Did LGND beat earnings last quarter?

In its 2026-05-14 report, LGND posted EPS of 1.63 USD versus a 1.84 USD estimate — a miss of 11.4%.

What is LGND's earnings track record?

Over the last 7 reported quarters with consensus data, LGND beat estimates 4 times (57%).

What is LGND's current P/E ratio and EPS?

LGND trades at a trailing P/E of 38.81 on trailing EPS of 7.723130312327114 USD.

What do analysts rate LGND?

Analyst consensus is "Buy" across 18 ratings (0 strong buy, 13 buy, 4 hold, 1 sell, 0 strong sell). Average 12-month price target: 302.17 USD.